PMC:7386875 / 54268-54450 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T397","span":{"begin":173,"end":181},"obj":"Disease"}],"attributes":[{"id":"A397","pred":"mondo_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Several other therapies with antiplatelet effects, including dipyridamole and nafamostat, are currently being evaluated for their potential role in reducing the severity of COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T17","span":{"begin":61,"end":73},"obj":"Chemical"},{"id":"T31968","span":{"begin":78,"end":88},"obj":"Chemical"}],"attributes":[{"id":"A87236","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_4653"},{"id":"A60539","pred":"chebi_id","subj":"T31968","obj":"http://purl.obolibrary.org/obo/CHEBI_135466"}],"text":"Several other therapies with antiplatelet effects, including dipyridamole and nafamostat, are currently being evaluated for their potential role in reducing the severity of COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T184","span":{"begin":0,"end":182},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Several other therapies with antiplatelet effects, including dipyridamole and nafamostat, are currently being evaluated for their potential role in reducing the severity of COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1786","span":{"begin":61,"end":73},"obj":"Chemical"},{"id":"1787","span":{"begin":78,"end":88},"obj":"Chemical"},{"id":"1801","span":{"begin":173,"end":181},"obj":"Disease"}],"attributes":[{"id":"A1786","pred":"tao:has_database_id","subj":"1786","obj":"MESH:D004176"},{"id":"A1787","pred":"tao:has_database_id","subj":"1787","obj":"MESH:C032855"},{"id":"A1801","pred":"tao:has_database_id","subj":"1801","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Several other therapies with antiplatelet effects, including dipyridamole and nafamostat, are currently being evaluated for their potential role in reducing the severity of COVID-19."}